Nasdaq Bbio News Today

Jennison Associates LLC trimmed its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 4.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 19,357 shares of the company’s stock after selling 944 shares during the quarter. Jennison Associates LLC’s holdings in BridgeBio Pharma were worth $781,000 at the end of […]

Moody Aldrich Partners LLC cut its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 9.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 124,984 shares of the company’s stock after selling 12,528 shares during the period. Moody Aldrich Partners LLC’s holdings in BridgeBio Pharma were worth $5,046,000 as of […]

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $29.76, but opened at $30.49. BridgeBio Pharma shares last traded at $30.08, with a volume of 180,372 shares traded. Wall Street Analyst Weigh In Several brokerages have issued reports on BBIO. […]

Raymond James initiated coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a research note issued to investors on Thursday, StockNewsAPI reports. The firm issued an outperform rating and a $45.00 price target on the stock. Other analysts have also recently issued reports about the stock. Citigroup lifted their price objective on shares […]

Rhumbline Advisers grew its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 1.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 179,759 shares of the company’s stock after acquiring an additional 1,924 shares during the period. […]

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.09), Briefing.com reports. The business had revenue of $1.74 million during the quarter, compared to the consensus estimate of $4.78 million. BridgeBio Pharma’s revenue for the […]

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) issued its earnings results on Thursday. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.09), Briefing.com reports. The company had revenue of $1.74 million for the quarter, compared to the consensus estimate of $4.78 million. The firm’s revenue for the quarter […]

Covestor Ltd raised its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 131.5% in the third quarter, Holdings Channel.com reports. The fund owned 9,587 shares of the company’s stock after acquiring an additional 5,446 shares during the period. Covestor Ltd’s holdings in BridgeBio Pharma were worth $252,000 at the end of the most […]

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twelve analysts that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month target […]

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) – Research analysts at Leerink Partnrs raised their FY2023 EPS estimates for shares of BridgeBio Pharma in a research report issued to clients and investors on Wednesday, February 7th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($3.80) per share for the year, up […]